Kat Lay is a Health Editor for The Times, focusing on national health issues in the United Kingdom. She covers a wide range of topics including access to healthcare, medical breakthroughs, public health concerns, and the impact of social and economic factors on health outcomes. Kat's articles provide informative and insightful analysis on the current state of healthcare in the UK.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Kat Lay's focus on healthcare, medical research, and the NHS in the UK suggests that she is likely to be interested in pitches related to advancements or updates within the healthcare industry. She heavily cites data and government announcements in her articles, indicating a preference for fact-based reporting.
Experts who can provide statistical insights into healthcare trends or offer commentary on government health policies may find success when reaching out to Kat. Additionally, those with expertise in medical conditions prevalent in the UK or relevant ongoing medical research could capture her attention.
Considering Kat’s national focus on the United Kingdom, experts with knowledge of its healthcare system and policies are more likely to resonate with her coverage.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Kat Lay
Propaganda is deterring people from accessing healthcare as Aids-related deaths rise 34% since 2010
Deadly virus is crossing borders and there are fears it could spread around the world
By: Kat Lay
‘Global gag rule’ and funding cuts will be ‘on different scale’ if Republicans win again, family-planning providers say
The move comes amid reports of disappointing results from trials for a treatment against the variant behind the current outbreak
By: Kat Lay
Health leaders warn that global response to virus is test case for equity and preparation for future pandemics
By: Kat Lay
World leaders will meet in New York this month to discuss growing antimicrobial resistance as researchers warn the development of replacement drugs is stalling
Child deaths from infections see ‘remarkable’ decline but AMR fatalities of over-70s likely to rise by 146%, study finds
Poll suggests half of Congolese have not heard of deadly disease, as conspiracy theories and rumours spread
By: Kat Lay
Gilead Sciences announces deal to manufacture generic versions of lenacapavir, but critics say it excludes many countries where incidence is highest
By: Kat Lay
New climate network will teach trainee doctors more about heatstroke, dengue and malaria and role of global warming in health
(833) 317-6278 
